Skip to main content

Table 1 Clinical, phenotypic and genotypic data for the linezolid-resistant Enterococci isolates investigated

From: Molecular characteristics of oxazolidinone resistance in enterococci from a multicenter study in China

Isolate no.

Organism

Isolation year

Hospitalb

Isolation site

STc

MICs (mg/L)a

Linezolid resistance genes

23S rRNA gene mutations

Other resistance genes

LNZ

P

AMP

VAN

TEC

DAP

TGC

LVX

ERY

HLG

Antibiotic resistance profiles

29462

E. faecalis

2009

ZRYH

urine

86

8

4

<=2

2

<=0.125

0.5

0.06

8

> 4

R

LVX, ERY

optrA

–

emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, cat, efrB, efrA, ermB, tetM, tet(L)

ZJ11066

E. faecalis

2011

ZJFY

blood

116

8

2

<=2

1

0.125

0.5

0.12

8

> 4

R

LVX, ERY

optrA

–

emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, dfrF, dfrG, dfrE, lnuG, lsaA, fexA, efrA, efrB, ermB, ermA1, tet(L), tetM

JS11041

E. faecium

2011

JSRM

urine

ND

8

> = 64

> = 32

0.5

0.25

2

0.06

8

> 4

R

P, AMP, LVX, ERY

–

–

ND

19113

E. faecalis

2011

SZRM

bile

ND

8

> = 64

> = 32

2

<=0.125

0.5

0.06

1

> 4

R

P, AMP, LVX, ERY

–

–

ND

ZJLRE1

E. faecium

2011

ZJFE

blood

ND

16

> = 64

> = 32

1

0.5

1

0.06

8

> 4

R

P, AMP, LVX, ERY

–

G2658 T

ND

1207_26W003

E. faecalis

2012

BJRM

urine

476

4

2

<=2

1

0.12

0.5

0.06

8

> 4

R

LVX, ERY

optrA

–

emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, mdtF, SAT-4, cat, fexA, efrB, efrA, ermA1, ermB, tet(L), tetM

1203_10W003

E. faecalis

2012

BJRM

urine

480

8

2

<=2

1

0.12

0.5

0.06

8

> 4

R

LVX, ERY

optrA

–

emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrA, efrB, ermB, ermA1, tetM, tet(L)

19677

E. faecalis

2012

SZRM

blood

59

8

2

<=2

0.5

0.12

0.5

0.12

0.03

> 4

R

ERY

optrA

–

emeA, dfrE, lsaA, fexA, efrA, efrB, ermA1, tetM, tet(L)

19506

E. faecium

2012

SZRM

wound

18

16

> = 64

> = 32

0.5

0.25

2

0.06

8

> 4

S

P, AMP, LVX, ERY

optrA

–

AAC(6′)-Ii, dfrG, efmA, msrC, fexA, ermA1

1202_13E004

E. faecalis

2012

BJRM

wound

416

16

8

<=2

2

<=0.125

0.5

0.12

8

> 4

R

LVX, ERY

optrA

–

emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, efrB, efrA, ermB, ermA1, tet(L), tetM

1202_21W014

E. faecalis

2012

BJRM

urine

21

8

4

<=2

2

<=0.125

0.5

0.12

8

> 4

R

LVX, ERY

optrA

–

emeA, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuG, lsaA, SAT-4, fexA, cat, efrA, efrB, ermB, tet(L)

SZ21494

E. faecalis

2012

SZRM

wound

67

8

4

<=2

1

<=0.125

1

0.06

1

> 4

S

ERY

optrA

–

emeA, dfrE, dfrG, lnuG, lsaA, fexA, cat, efrA, efrB, ermB, ermA1, tetM, tet(L)

XM2013_71028

E. faecalis

2013

XMDY

wound

16

8

2

<=2

1

<=0.125

1

0.06

0.5

> 4

R

ERY

optrA

–

emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, ANT(9)-Ia, aad(6), dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermB, ermA1, tetM

XM2013_42321

E. faecalis

2013

XMDY

urine

585

16

4

<=2

1

<=0.125

0.5

0.06

8

> 4

R

LVX, ERY

optrA

–

emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrE, dfrG, lmrD, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(L)

TZ2

E. faecalis

2013

TZSY

blood

476

8

2

<=2

1

<=0.125

0.5

0.12

8

> 4

R

LVX, ERY

optrA

–

emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermA1, ermB, tet(L), tetM

WHXH

E. faecalis

2013

WHDS

blood

476

8

4

<=2

2

<=0.125

0.5

0.12

8

> 4

S

LVX, ERY

optrA

–

emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(9)-Ia, dfrE, dfrG, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(C), tet(L)

  1. aMICs, the minimal inhibitory concentrations; LNZ, linezolid, susceptible (S): ≤ 2 mg/L, intermediate (I): 4 mg/L, resistant (R): ≥ 8 mg/L; P, penicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; AMP, ampicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; VAN, vancomycin, S: ≤ 4 mg/L, I: 8–16 mg/L, R: ≥ 32 mg/L; TEC, teicoplanin, S: ≤ 8 mg/L, I: 16 mg/L, R: ≥ 32 mg/L; DAP, S: ≤ 1 mg/L, susceptible-dose dependent (SDD): 2–4 mg/L, R: ≥ 8 mg/L; TGC, tigecycline, no breakpoint in CLSI M100; LVX, levofloxacin, S: ≤ 2 mg/L, I: 4 mg/L, R: ≥ 8 mg/L; ERY, erythromycin, S: ≤ 0.5 mg/L, I: 1–4 mg/L, R: ≥ 8 mg/L; HLG, high-level gentamycin (500 mg/L); −, negative; ND, not determined
  2. bZRYH, China-Japan Friendship Hospital; ZJFY, 1st Affiliated Hospital of Zhejiang University; JSRM, Jiangsu Province Hospital; SZRM, Shenzhen People’s Hospital; ZJFE, 2nd Affiliated Hospital of Zhejiang University; BJRM, Peking University People’s Hospital; XMDY, 1st Affiliated Hospital of Xiamen University; TZSY, Taizhou Hospital of Zhejiang Province; WHDS, Wuhan Fourth Hospital
  3. cST sequence type, ND not determined
Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us